KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Cash (2016 - 2025)

Historic Change in Cash for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $357.8 million.

  • Halozyme Therapeutics' Change in Cash rose 116660.7% to $357.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.3 million, marking a year-over-year increase of 32129.03%. This contributed to the annual value of -$2.5 million for FY2024, which is 9783.37% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Change in Cash stood at $357.8 million for Q3 2025, which was up 116660.7% from -$114.5 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Change in Cash registered a high of $357.8 million during Q3 2025, and its lowest value of -$373.0 million during Q4 2021.
  • For the 5-year period, Halozyme Therapeutics' Change in Cash averaged around $14.3 million, with its median value being $23.2 million (2024).
  • As far as peak fluctuations go, Halozyme Therapeutics' Change in Cash skyrocketed by 239016.86% in 2021, and later plummeted by 1548959.28% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Change in Cash stood at -$373.0 million in 2021, then surged by 123.34% to $87.0 million in 2022, then tumbled by 279.07% to -$155.9 million in 2023, then surged by 75.32% to -$38.5 million in 2024, then surged by 1030.13% to $357.8 million in 2025.
  • Its last three reported values are $357.8 million in Q3 2025, -$114.5 million for Q2 2025, and $60.5 million during Q1 2025.